Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2008

View Archived Issues

New compounds for the treatment of cancer disclosed in recent patent literature

Genetic variations may influence golimumab efficacy in severe asthma

Mepolizumab investigated in eosinophilic esophagitis and nasal polyposis

AGI completes optimization phase of development of AGI-010 for nocturnal acid breakthrough

DiObex and Camurus to develop DIO-901 using FluidCrystal technology

Tetravalent dengue fever vaccine safe and immunogenic in Flavivirus-naive children

Studies elucidate role of smooth muscle PPARgamma in cardiovascular function

Molecular processes identified in anxiety and alcoholism comorbidity

Diamyd receives Swiss approval to commence phase III diabetes vaccine studies

Lipsovir shown to prevent cold sores in phase III trial

Peptimmune completes phase I novel peptide copolymer trial in MS

NanoBio reports positive phase IIb results for NB-001 in herpes labialis

Onyvax completes enrollment in European phase IIb Onyvax-P trial

MEDI-528 begins phase IIa study for asthma

AEG-33773 enters clinical testing for diabetic neuropathic pain

Oramed cleared for phase IIa study of oral insulin

ReNeuron updates strategy for ReN-001

Axis-Shield HbA1c test approved by FDA

Recent Emisphere patent describes novel drug delivery agents

Epix discontinues PRX-00023 development and provides pipeline update

Novel agents for autoimmune diseases reported in recent Novartis patent

Genzyme withdraws EU application to extend Evoltra and plans to resubmit

Mifamurtide now available through compassionate access study

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...